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Abstract
Background:  The head and neck is the second most common region for the extra-nodal
lymphomas after that of gastrointestinal tract. Approximately 2.5% of malignant lymphoma arises
in the oral and para-oral region. In this paper we report two cases of early stage head and neck
lymphoma which were managed successfully with chemotherapy and a review of the related
literature.
Cases presentation: The first case concerns a 48 years male patient having a diffuse large B-Cell
lymphoma of the oropharynx at early bulky stage. This patient was managed successfully with 7 of
Rituximab 375 mg/m2, Cyclophosphamide 750 mg/m2 d1, Doxorubicine 50 mg/m2 d1, Vincristine
1.4 mg/m2 d1, and prednisone 50 mg/m2 d1-5 (RCHOP) regimen. The second case concerns a 50
years female patient having the nasal natural killer (NK)/T-cell lymphoma of the left nasal pit at early
stage. This case was managed successfully with 6 of Cyclophosphamide 750 mg/m2  d1,
Doxorubicine 50 mg/m2 d1, Vincristine 1.4 mg/m2 d1, and prednisone 50 mg/m2 d1-5 (CHOP)
regimen.
Conclusion: These two cases highlight the important role of CHOP based chemotherapy for
achieving successful treatment cure for patients having an early stage head and neck lymphoma.
Introduction
Lymphomas are malignant neoplasms of the lymphocyte
cell lines. They mainly involve lymph nodes, spleen and
other non-haemopoietic tissues. They are mainly classi-
fied as either Hodgkin's or non-Hodgkin's lymphoma
(NHL), and of either B-lymphocyte or T-lymphocyte ori-
gin. The head and neck is the second most common
region for the extra-nodal lymphomas after that of gas-
trointestinal tract. Approximately 2.5% of malignant lym-
phoma arise in the oral and paraoral region, mainly in the
form of Waldeyer's ring (ie, the tonsils and base,
nasopharynx and base of the tongue) [1]. The diffuse large
B-cell lymphoma (DLBCL) appeares to be the most com-
mon type of primary oral and paraoral NHL [1,2]. In this
paper, we will present two cases of early stage head and
neck lymphoma, the first with DLBCL of the oro-pharynx
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at early bulky stage and the second with nasal NK/T cell
lymphoma of the left nasal pit at early stage. The two
patients were managed successfully with CHOP based
chemotherapy treatment.
Case 1
A 48 years old man, was admitted to the National Institute
of Oncology hospital with enlarged cervical lymph nodes,
dysphagia, dysphonia and having continuous weight loss
for 5 months. The patient had an ECOG performance sta-
tus equal to 2.0 [3]. A physical examination revealed a
fixed cervical masse measuring 13 cm long and 10 cm
large (figure 1). Otolaryngology examination showed an
ulcerative-vegetative tumour on the right posterolateral
wall of the oropharynx. The tumour spread to the soft pal-
ate ant hard palate filling partially the nasopharynx. Head
and neck computed tomography scan showed a large tis-
sular oropharyngeal tumour (Figure 2). The oropharyn-
geal mass invaded the nasopharynx (Figure 3). This
process was associated by the infiltration of the tonsillar
fossa and the parotid space by a bulky cervical mass (13
cm × 10 cm) growing on the right cervical region vast,
starting from the submaxillary region up to the supra-cla-
vicular region (Figure 2). The oropharyngeal biopsy was
performed. Histological and immunohistochemistry
studies showed diffuse large B-cell Lymphoma of the
oropharynx according to the Revised European-American
Classification of Lymphoid Neoplasms/World Health
Organisation classification of lymphoid neoplasms
(REAL/WHO). Most of the neoplasic cells were positive
for CD-20 and for leucocyte common antigen (LCA) anti-
body. Computed tomography of the chest, abdomen and
pelvis was normal. A bone marrow biopsy showed no
abnormalities. The patient was staged IIEXB according to
the Ann Arbor Staging system. The patient received 7
cycles of standard Rituximab 375 mg/m2, Cyclophospha-
mide 750 mg/m2 d1, Doxorubicine 50 mg/m2 d1, Vincris-
tine 1.4 mg/m2  d1, and prednisone 50 mg/m2  d1-5
(RCHOP) regimen with complete response. He remained
Right cervical masse fixed, bulky, measured 13 × 10 cm in  diameter Figure 1
Right cervical masse fixed, bulky, measured 13 × 10 
cm in diameter.
Computed tomography of the head and neck shows the  oropharyngeal process and a bulky cervical mass Figure 2
Computed tomography of the head and neck shows 
the oropharyngeal process and a bulky cervical mass.
Computed tomography of the head and neck shows the  involvement of the nasopharynx by the oropharyngeal proc- ess Figure 3
Computed tomography of the head and neck shows 
the involvement of the nasopharynx by the oropha-
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disease free, until now, 22 months after the end of chem-
otherapy (Figure 4).
Case 2
A 50 years old female was admitted to the Oncology hos-
pital. She had 5 months history of running nose (clear liq-
uid at the beginning then becoming yellowish at the end).
Evolution was marked by a foreign body sensation in the
nasal passages without general signs. Naso-fibroscopy
examination showed a process of the left nasal pit,
inserted into the nasal septum. Histological and immuno-
histochemistry studies showed the signs of malignant
non-Hodgkin lymphoma NK/T nasal type, with strong
expression of CD3 and CD56 (figure 5) (Figure 6) (Figue
7). Head and neck computed tomography scan showed a
tumour of the left nasal pit with a mass volume measuring
4 cm × 2 cm × 3 cm. Computed tomography of the chest,
abdomen and pelvis was normal. A bone marrow biopsy
showed no abnormalities. The patient was staged IE
according to the Ann Arbor Staging system. The patient
received 6 cycles of standard Cyclophosphamide 750 mg/
m2 d1, Doxorubicine 50 mg/m2 d1, Vincristine 1.4 mg/m2
d1, and prednisone 50 mg/m2 d1-5 (CHOP) regimen. The
response to the treatment was successful. The patient, 6
months after the end of chemotherapy, remains disease
free. She is continuously followed by our group up to
now.
Discussion
The head and neck is the second most common region for
the extra-nodal lymphomas. Approximately 2.5% of
malignant lymphoma arises in the oral and paraoral
region, mainly in the form of Waldeyer's ring (ie, the ton-
sils, nasopharynx and base of the tongue) [1].
The DLBCL is the most common type of primary oral and
paraoral NHL [1,2]. Nasal non-Hodgkin's lymphoma is a
rare clinical entity in western countries, but the disease is
common in East Asian countries and Latin America [4]. In
the revised European-American lymphoma and WHO
classification, primary nasal and nasal type NK/T-cell lym-
phoma are recognized as distinct clinico-pathologic enti-
ties [4].
The right cervical region was free from the disease 22 month  after the end of chemotherapy Figure 4
The right cervical region was free from the disease 
22 month after the end of chemotherapy.
NK/T-cell lymphoma, angiocentric infiltrate of small lym- phocytes and atypical cells Figure 5
NK/T-cell lymphoma, angiocentric infiltrate of small 
lymphocytes and atypical cells.
Angiocentric marking by CD 56 Figure 6
Angiocentric marking by CD 56.Cases Journal 2008, 1:426 http://www.casesjournal.com/content/1/1/426
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Several factors are known to increase NHL risk including
the Epstein-Barr virus [5]. In one serie, primary oral and
para-oral lymphoma was most commonly presented as a
painless local mass that gradually increased in size with
superficial ulceration. Most of the patients with a tonsillar
NHL complained of dysphagia or sensation of a foreign
body in the throat [6]. Our first patient presented cervical
lymph nodes, dysphagia, dysphonia and weight loss with
ulcerative-vegetative tumour (otolaryngology examina-
tion). Therefore, the symptoms were similar to those of a
squamous cancer, which can only be differenciated by
biopsy in the oropharynx.
The presence of positive staining for leukocyte common
antigen (LCA) in histological specimen distinguishes
malignant lymphomas from non-lymphoide neoplasms.
Diffuse large B-cell lymphoma was most commonly posi-
tive for CD20 and CD79a and less commonly positive for
germinal centre cell markers CD10 and BCL6. A small
minority of cases showed a translocation between the
BCL-2 gene on chromosome 18 and the IgH gene on chro-
mosome 14, t(14;18) [1]. Nasal type NK/T-cell lym-
phoma arises as consequence of malignant
transformation of NK-cells (NKC) which express markers
CD 56+ (Neural cell adhesion molecule), TIA (T-cell intra-
cellular antigen-A), and lack T-cell receptor (TCR) gene
rearrangements, hence distinguishing the tumour from T-
cell lymphomas [7,8]. The patient showed positive stain-
ing for CD3 and CD56. Most commonly, this tumour
affects the nose and mid face although the disease can also
arises on the skin, the gastro-intestinal tract, the testicle,
the CNS, the lung, the salivary glands, the bone marrow,
and the larynx [8].
Computed thomography of the head and neck, chest,
abdomen and pelvis is the mainstay of staging for oropha-
ryngeal lymphoma as well as other nodal lymphomas.
Bone marrow biopsy is equally mandatory for staging.
Concurrent positron emission tomography (PET) with
18F-fluorodeoxyglucose (FDG) and computed tomogra-
phy (PET/CT) is a useful method for staging and assess-
ment of therapeutic response [9].
In general, the standard treatment for patients with early
stage diffuse large-cell lymphoma is chemotherapy (CT)
followed by involved field radiotherapy (RT) [10,11].
Treatment recommendation for diffuse large B-cell lym-
phoma is generally identical for nodal and extra nodal
diseases [12]. The use of chemotherapy is based on the
principle that DLBCL of the head and neck must be con-
sidered a localised manifestation of systemic disease.
Patients with stage I and II DLBCL (not bulky) usually do
well with systemic chemotherapy followed by radiother-
apy [1]. The prognosis for such patients is much better
than that of patients with obvious systemic disease [13].
Patients with advanced-stage (bulky stage II, stage III and
IV) must be treated by combined chemotherapy. Eight of
RCHOP regimen should be considered as the standard
treatment for patients with advanced stage DLBCL [14].
Our patient was staged IIXE bulky and was treated by 7
cycles of RCHOP regimen with good control of the disease
until now (22 months after the end of chemotherapy).
Nasal NK/T cell lymphomas are rare, and the optimal
treatment has still not been clearly established. The man-
agement of Nasal NK/T-cell lymphomas has been based
largely on extrapolation from the experience with aggres-
sive NHL. Ongoing studies has been limited to small insti-
tutional series, heterogeneous treatments and variable
diagnostic criteria [10,11]. Overall, for patients with the
early stage disease, chemotherapy (CT) followed by
involved field radiotherapy (RT) is considered the stand-
ard treatment [9,10]. Our patient achieved complete and
successful response after the end of 6 cycles of chemother-
apy.
According to the international prognostic index (IPI)
established for patients aged less than 60 years, the out-
come of patients with extra nodal DLBCL is similar to that
of patients with nodal DLBCL [12]. Nasal NK/T-cell lym-
phoma shows a more aggressive behaviour, poorer prog-
nosis and frequent relapses.
Conclusion
These two cases highlight the important role of CHOP
based chemotherapy for achieving the cure for patients
with localised stage diffuse large B-cell and T-cell lym-
phoma of the head and neck.
Angiocentric marking by CD 3 Figure 7
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